The study, published Jan. 30 in Cureus, evaluated incidents of prostate cancer between January 2010 and December 2019 in patients with and without a history of C. difficile infection. A total of 79,226 patients were identified and separated into infected and control groups and subsequently matched by antibiotic treatment.
In the C. difficile group, 1.62 percent developed prostate cancer, while 3.95 percent developed prostate cancer in the control group.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
